Skip to main content
NCBI home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1996 Oct;80(10):922–926. doi: 10.1136/bjo.80.10.922

Thyroid eye disease.

D H Char 1
PMCID: PMC505652  PMID: 8976707

Full text

PDF
922

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold K., Tandon N., McIntosh R. S., Elisei R., Ludgate M., Weetman A. P. T cell responses to orbital antigens in thyroid-associated ophthalmopathy. Clin Exp Immunol. 1994 May;96(2):329–334. doi: 10.1111/j.1365-2249.1994.tb06562.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bahn R. S., Dutton C. M., Heufelder A. E., Sarkar G. A genomic point mutation in the extracellular domain of the thyrotropin receptor in patients with Graves' ophthalmopathy. J Clin Endocrinol Metab. 1994 Feb;78(2):256–260. doi: 10.1210/jcem.78.2.7508946. [DOI] [PubMed] [Google Scholar]
  3. Bahn R. S., Heufelder A. E. Pathogenesis of Graves' ophthalmopathy. N Engl J Med. 1993 Nov 11;329(20):1468–1475. doi: 10.1056/NEJM199311113292007. [DOI] [PubMed] [Google Scholar]
  4. Bahn R. S., Heufelder A. E. Retroocular fibroblasts: important effector cells in Graves' ophthalmopathy. Thyroid. 1992 Spring;2(1):89–94. doi: 10.1089/thy.1992.2.89. [DOI] [PubMed] [Google Scholar]
  5. Bahn R. S. The fibroblast is the target cell in the connective tissue manifestations of Graves' disease. Int Arch Allergy Immunol. 1995 Mar;106(3):213–218. doi: 10.1159/000236845. [DOI] [PubMed] [Google Scholar]
  6. Bartalena L., Marcocci C., Bogazzi F., Panicucci M., Lepri A., Pinchera A. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med. 1989 Nov 16;321(20):1349–1352. doi: 10.1056/NEJM198911163212001. [DOI] [PubMed] [Google Scholar]
  7. Bartalena L., Marcocci C., Chiovato L., Laddaga M., Lepri G., Andreani D., Cavallacci G., Baschieri L., Pinchera A. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab. 1983 Jun;56(6):1139–1144. doi: 10.1210/jcem-56-6-1139. [DOI] [PubMed] [Google Scholar]
  8. Bartalena L., Martino E., Marcocci C., Bogazzi F., Panicucci M., Velluzzi F., Loviselli A., Pinchera A. More on smoking habits and Graves' ophthalmopathy. J Endocrinol Invest. 1989 Nov;12(10):733–737. doi: 10.1007/BF03350047. [DOI] [PubMed] [Google Scholar]
  9. Bartley G. B. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc. 1994;92:477–588. [PMC free article] [PubMed] [Google Scholar]
  10. Benning H., Lieb W., Kahaly G., Grehn F. Farbduplexsonographische Befunde bei Patienten mit endokriner Orbitopathie. Ophthalmologe. 1994 Feb;91(1):20–25. [PubMed] [Google Scholar]
  11. Bernard N. F., Nygen T. N., Tyutyunikov A., Stolarski C., Scalise D., Genovese C., Hayes M. B., Ludgate M., Wall J. R. Antibodies against 1D, a recombinant 64-kDa membrane protein, are associated with ophthalmopathy in patients with thyroid autoimmunity. Clin Immunol Immunopathol. 1994 Mar;70(3):225–233. doi: 10.1006/clin.1994.1033. [DOI] [PubMed] [Google Scholar]
  12. Boucher A., Bernard N., Zhang Z. G., Rodien P., Salvi M., Wall J. R. Nature of 64 kDa eye muscle and thyroid membrane proteins and their significance in thyroid-associated ophthalmopathy--an hypothesis. Autoimmunity. 1993;16(2):79–82. doi: 10.3109/08916939308993314. [DOI] [PubMed] [Google Scholar]
  13. Bromberg N., Romaldini J. H., Werner R. S., Sgarbi J. A., Werner M. C. The evolution of Graves' ophthalmopathy during treatment with antithyroid drug alone and combined with triiodothyronine. J Endocrinol Invest. 1992 Mar;15(3):191–195. doi: 10.1007/BF03348703. [DOI] [PubMed] [Google Scholar]
  14. Burch H. B., Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev. 1993 Dec;14(6):747–793. doi: 10.1210/edrv-14-6-747. [DOI] [PubMed] [Google Scholar]
  15. Char D. H. The ophthalmopathy of Graves' disease. Med Clin North Am. 1991 Jan;75(1):97–119. doi: 10.1016/s0025-7125(16)30474-6. [DOI] [PubMed] [Google Scholar]
  16. Ciocca D. R., Oesterreich S., Chamness G. C., McGuire W. L., Fuqua S. A. Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J Natl Cancer Inst. 1993 Oct 6;85(19):1558–1570. doi: 10.1093/jnci/85.19.1558. [DOI] [PubMed] [Google Scholar]
  17. DeGroot L. J., Gorman C. A., Pinchera A., Bartalena L., Marcocci C., Wiersinga W. M., Prummel M. F., Wartofsky L., Marocci C [corrected to Marcocci C. ]. Therapeutic controversies. Retro-orbital radiation and radioactive iodide ablation of the thyroid may be good for Graves' ophthalmopathy. J Clin Endocrinol Metab. 1995 Feb;80(2):339–340. doi: 10.1210/jcem.80.2.7677823. [DOI] [PubMed] [Google Scholar]
  18. DeGroot L. J., Mangklabruks A., McCormick M. Comparison of RA 131I treatment protocols for Graves' disease. J Endocrinol Invest. 1990 Feb;13(2):111–118. doi: 10.1007/BF03349519. [DOI] [PubMed] [Google Scholar]
  19. Elisei R., Weightman D., Kendall-Taylor P., Vassart G., Ludgate M. Muscle autoantigens in thyroid associated ophthalmopathy: the limits of molecular genetics. J Endocrinol Invest. 1993 Jul-Aug;16(7):533–540. doi: 10.1007/BF03348900. [DOI] [PubMed] [Google Scholar]
  20. Feliciello A., Porcellini A., Ciullo I., Bonavolontà G., Avvedimento E. V., Fenzi G. Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue. Lancet. 1993 Aug 7;342(8867):337–338. doi: 10.1016/0140-6736(93)91475-2. [DOI] [PubMed] [Google Scholar]
  21. Foss A. J., Fisher E. W., McDonald N., Lawson J., Gregson R., Fells P. The site of the autoantigen in dysthyroid eye disease: a significant negative. Eye (Lond) 1993;7(Pt 6):806–808. doi: 10.1038/eye.1993.189. [DOI] [PubMed] [Google Scholar]
  22. Fries P. D., Fohrman D. S., Char D. H. Phorbol ester-induced orbital myositis. Arch Ophthalmol. 1987 Sep;105(9):1273–1276. doi: 10.1001/archopht.1987.01060090131043. [DOI] [PubMed] [Google Scholar]
  23. Heufelder A. E., Bahn R. S. Detection and localization of cytokine immunoreactivity in retro-ocular connective tissue in Graves' ophthalmopathy. Eur J Clin Invest. 1993 Jan;23(1):10–17. doi: 10.1111/j.1365-2362.1993.tb00712.x. [DOI] [PubMed] [Google Scholar]
  24. Heufelder A. E., Bahn R. S. Evidence for the presence of a functional TSH-receptor in retroocular fibroblasts from patients with Graves' ophthalmopathy. Exp Clin Endocrinol. 1992;100(1-2):62–67. doi: 10.1055/s-0029-1211178. [DOI] [PubMed] [Google Scholar]
  25. Heufelder A. E., Bahn R. S. Graves' immunoglobulins and cytokines stimulate the expression of intercellular adhesion molecule-1 (ICAM-1) in cultured Graves' orbital fibroblasts. Eur J Clin Invest. 1992 Aug;22(8):529–537. doi: 10.1111/j.1365-2362.1992.tb01501.x. [DOI] [PubMed] [Google Scholar]
  26. Heufelder A. E., Bahn R. S. Modulation of Graves' orbital fibroblast proliferation by cytokines and glucocorticoid receptor agonists. Invest Ophthalmol Vis Sci. 1994 Jan;35(1):120–127. [PubMed] [Google Scholar]
  27. Heufelder A. E., Bahn R. S., Smith T. J. Regulation by glucocorticoids of interferon gamma-induced HLA-DR antigen expression in cultured human orbital fibroblasts. Clin Endocrinol (Oxf) 1992 Jul;37(1):59–63. doi: 10.1111/j.1365-2265.1992.tb02284.x. [DOI] [PubMed] [Google Scholar]
  28. Heufelder A. E., Wenzel B. E., Bahn R. S. Glucocorticoids modulate the synthesis and expression of a 72 kDa heat shock protein in cultured Graves' retroocular fibroblasts. Acta Endocrinol (Copenh) 1993 Jan;128(1):41–50. doi: 10.1530/acta.0.1280041. [DOI] [PubMed] [Google Scholar]
  29. Heufelder A. E., Wenzel B. E., Gorman C. A., Bahn R. S. Detection, cellular localization, and modulation of heat shock proteins in cultured fibroblasts from patients with extrathyroidal manifestations of Graves' disease. J Clin Endocrinol Metab. 1991 Oct;73(4):739–745. doi: 10.1210/jcem-73-4-739. [DOI] [PubMed] [Google Scholar]
  30. Hiromatsu Y., Fukazawa H., Guinard F., Salvi M., How J., Wall J. R. A thyroid cytotoxic antibody that cross-reacts with an eye muscle cell surface antigen may be the cause of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 1988 Sep;67(3):565–570. doi: 10.1210/jcem-67-3-565. [DOI] [PubMed] [Google Scholar]
  31. Hudson H. L., Levin L., Feldon S. E. Graves exophthalmos unrelated to extraocular muscle enlargement. Superior rectus muscle inflammation may induce venous obstruction. Ophthalmology. 1991 Oct;98(10):1495–1499. doi: 10.1016/s0161-6420(91)32099-2. [DOI] [PubMed] [Google Scholar]
  32. Hägg E., Asplund K. Is endocrine ophthalmopathy related to smoking? Br Med J (Clin Res Ed) 1987 Sep 12;295(6599):634–635. doi: 10.1136/bmj.295.6599.634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Imai Y., Odajima R., Inoue Y., Shishiba Y. Effect of growth factors on hyaluronan and proteoglycan synthesis by retroocular tissue fibroblasts of Graves' ophthalmopathy in culture. Acta Endocrinol (Copenh) 1992 Jun;126(6):541–552. doi: 10.1530/acta.0.1260541. [DOI] [PubMed] [Google Scholar]
  34. Ivy H. K. Medical approach to ophthalmopathy of Graves' disease. Mayo Clin Proc. 1972 Dec;47(12):980–985. [PubMed] [Google Scholar]
  35. Kahaly G., Schrezenmeir J., Krause U., Schweikert B., Meuer S., Muller W., Dennebaum R., Beyer J. Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest. 1986 Oct;16(5):415–422. doi: 10.1111/j.1365-2362.1986.tb01016.x. [DOI] [PubMed] [Google Scholar]
  36. Karlsson F., Westermark K., Dahlberg P. A., Jansson R., Enoksson P. Ophthalmopathy and thyroid stimulation. Lancet. 1989 Sep 16;2(8664):691–691. doi: 10.1016/s0140-6736(89)90945-8. [DOI] [PubMed] [Google Scholar]
  37. Kendler D. L., Rootman J., Huber G. K., Davies T. F. A 64 kDa membrane antigen is a recurrent epitope for natural autoantibodies in patients with Graves' thyroid and ophthalmic diseases. Clin Endocrinol (Oxf) 1991 Dec;35(6):539–547. doi: 10.1111/j.1365-2265.1991.tb00941.x. [DOI] [PubMed] [Google Scholar]
  38. Kiljanski J. I., Nebes V., Wall J. R. The ocular muscle cell is a target of the immune system in endocrine ophthalmopathy. Int Arch Allergy Immunol. 1995 Mar;106(3):204–212. doi: 10.1159/000236844. [DOI] [PubMed] [Google Scholar]
  39. Marcocci C., Bartalena L., Bogazzi F., Bruno-Bossio G., Pinchera A. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism. Thyroid. 1992 Summer;2(2):171–178. doi: 10.1089/thy.1992.2.171. [DOI] [PubMed] [Google Scholar]
  40. McIver B., Rae P., Beckett G., Wilkinson E., Gold A., Toft A. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N Engl J Med. 1996 Jan 25;334(4):220–224. doi: 10.1056/NEJM199601253340403. [DOI] [PubMed] [Google Scholar]
  41. McLachlan S. M., Bahn R., Rapoport B. Endocrine ophthalmopathy: a re-evaluation of the association with thyroid autoantibodies. Autoimmunity. 1992;14(2):143–148. doi: 10.3109/08916939209083133. [DOI] [PubMed] [Google Scholar]
  42. Mendlovic D. B., Saeed Zafar M. Ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med. 1992 Oct 29;327(18):1320–1321. doi: 10.1056/NEJM199210293271818. [DOI] [PubMed] [Google Scholar]
  43. Metcalfe R. A., Weetman A. P. Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy. Clin Endocrinol (Oxf) 1994 Jan;40(1):67–72. doi: 10.1111/j.1365-2265.1994.tb02445.x. [DOI] [PubMed] [Google Scholar]
  44. Metz H. S., Woolf P. D., Patton M. L. Endocrine ophthalmomyopathy in adolescence. J Pediatr Ophthalmol Strabismus. 1982 Jan-Feb;19(1):58–60. doi: 10.3928/0191-3913-19820101-14. [DOI] [PubMed] [Google Scholar]
  45. Nunery W. R., Martin R. T., Heinz G. W., Gavin T. J. The association of cigarette smoking with clinical subtypes of ophthalmic Graves' disease. Ophthal Plast Reconstr Surg. 1993 Jun;9(2):77–82. doi: 10.1097/00002341-199306000-00001. [DOI] [PubMed] [Google Scholar]
  46. Parmentier M., Libert F., Maenhaut C., Lefort A., Gérard C., Perret J., Van Sande J., Dumont J. E., Vassart G. Molecular cloning of the thyrotropin receptor. Science. 1989 Dec 22;246(4937):1620–1622. doi: 10.1126/science.2556796. [DOI] [PubMed] [Google Scholar]
  47. Paschke R., Elisei R., Vassart G., Ludgate M. Lack of evidence supporting the presence of mRNA for the thyrotropin receptor in extra-ocular muscle. J Endocrinol Invest. 1993 May;16(5):329–332. doi: 10.1007/BF03348847. [DOI] [PubMed] [Google Scholar]
  48. Paschke R., Vassart G., Ludgate M. Current evidence for and against the TSH receptor being the common antigen in Graves' disease and thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 1995 Jun;42(6):565–569. doi: 10.1111/j.1365-2265.1995.tb02681.x. [DOI] [PubMed] [Google Scholar]
  49. Pequegnat E. P., Mayberry W. E., McConahey W. M., Wyse E. P. Large doses of radioiodide in Graves' disease: effect on ophthalmopathy and long-acting thyroid stimulator. Mayo Clin Proc. 1967 Dec;42(12):802–811. [PubMed] [Google Scholar]
  50. Perros P., Crombie A. L., Matthews J. N., Kendall-Taylor P. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol (Oxf) 1993 Apr;38(4):367–372. doi: 10.1111/j.1365-2265.1993.tb00516.x. [DOI] [PubMed] [Google Scholar]
  51. Petersen I. A., Kriss J. P., McDougall I. R., Donaldson S. S. Prognostic factors in the radiotherapy of Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):259–264. doi: 10.1016/0360-3016(90)90532-o. [DOI] [PubMed] [Google Scholar]
  52. Prummel M. F., Mourits M. P., Berghout A., Krenning E. P., van der Gaag R., Koornneef L., Wiersinga W. M. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med. 1989 Nov 16;321(20):1353–1359. doi: 10.1056/NEJM198911163212002. [DOI] [PubMed] [Google Scholar]
  53. Prummel M. F., Wiersinga W. M. Medical management of Graves' ophthalmopathy. Thyroid. 1995 Jun;5(3):231–234. doi: 10.1089/thy.1995.5.231. [DOI] [PubMed] [Google Scholar]
  54. Prummel M. F., Wiersinga W. M., Van der Gaag R., Mourits M. P., Koornneef L. Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy. Clin Exp Immunol. 1992 Jun;88(3):405–409. doi: 10.1111/j.1365-2249.1992.tb06462.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Ross P. V., Koenig R. J., Arscott P., Ludgate M., Waier M., Nelson C. C., Kaplan M. M., Baker J. R., Jr Tissue specificity and serologic reactivity of an autoantigen associated with autoimmune thyroid disease. J Clin Endocrinol Metab. 1993 Aug;77(2):433–438. doi: 10.1210/jcem.77.2.8345048. [DOI] [PubMed] [Google Scholar]
  56. Ross P. V., Koenig R. J., Arscott P., Ludgate M., Waier M., Nelson C. C., Kaplan M. M., Baker J. R., Jr Tissue specificity and serologic reactivity of an autoantigen associated with autoimmune thyroid disease. J Clin Endocrinol Metab. 1993 Aug;77(2):433–438. doi: 10.1210/jcem.77.2.8345048. [DOI] [PubMed] [Google Scholar]
  57. Salvi M., Zhang Z. G., Haegert D., Woo M., Liberman A., Cadarso L., Wall J. R. Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities. J Clin Endocrinol Metab. 1990 Jan;70(1):89–94. doi: 10.1210/jcem-70-1-89. [DOI] [PubMed] [Google Scholar]
  58. Schifferdecker E., Ketzler-Sasse U., Boehm B. O., Ronsheimer H. B., Scherbaum W. A., Schöffling K. Re-evaluation of eye muscle autoantibody determination in Graves' ophthalmopathy: failure to detect a specific antigen by use of enzyme-linked immunosorbent assay, indirect immunofluorescence, and immunoblotting techniques. Acta Endocrinol (Copenh) 1989 Nov;121(5):643–650. doi: 10.1530/acta.0.1210643. [DOI] [PubMed] [Google Scholar]
  59. Segers O., Musch W., Schoors D. F. Early complications of radioiodine treatment for hyperthyroidism. Acta Clin Belg. 1993;48(4):253–258. [PubMed] [Google Scholar]
  60. Shine B., Fells P., Edwards O. M., Weetman A. P. Association between Graves' ophthalmopathy and smoking. Lancet. 1990 May 26;335(8700):1261–1263. doi: 10.1016/0140-6736(90)91315-2. [DOI] [PubMed] [Google Scholar]
  61. Sridama V., DeGroot L. J. Treatment of Graves' disease and the course of ophthalmopathy. Am J Med. 1989 Jul;87(1):70–73. doi: 10.1016/s0002-9343(89)80485-1. [DOI] [PubMed] [Google Scholar]
  62. Tallstedt L., Lundell G., Blomgren H., Bring J. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol. 1994 May;130(5):494–497. doi: 10.1530/eje.0.1300494. [DOI] [PubMed] [Google Scholar]
  63. Tallstedt L., Lundell G., Tørring O., Wallin G., Ljunggren J. G., Blomgren H., Taube A. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992 Jun 25;326(26):1733–1738. doi: 10.1056/NEJM199206253262603. [DOI] [PubMed] [Google Scholar]
  64. Tandon N., Yan S. L., Arnold K., Metcalfe R. A., Weetman A. P. Immunoglobulin class and subclass distribution of eye muscle and fibroblast antibodies in patients with thyroid-associated ophthalmopathy. Clin Endocrinol (Oxf) 1994 May;40(5):629–639. doi: 10.1111/j.1365-2265.1994.tb03015.x. [DOI] [PubMed] [Google Scholar]
  65. Tellez M., Cooper J., Edmonds C. Graves' ophthalmopathy in relation to cigarette smoking and ethnic origin. Clin Endocrinol (Oxf) 1992 Mar;36(3):291–294. doi: 10.1111/j.1365-2265.1992.tb01445.x. [DOI] [PubMed] [Google Scholar]
  66. Trokel S., Kazim M., Moore S. Orbital fat removal. Decompression for Graves orbitopathy. Ophthalmology. 1993 May;100(5):674–682. doi: 10.1016/s0161-6420(93)31589-7. [DOI] [PubMed] [Google Scholar]
  67. Walfish P. G., Tseng K. H. Intrathyroidal activated (Ia+) T-lymphocyte CD+ subsets and B cells in Graves' hyperthyroidism respond rapidly to propylthiouracil therapy: demonstration using fine needle aspirates and two-colour laser flow cytometry. Autoimmunity. 1992;13(1):35–41. doi: 10.3109/08916939209014633. [DOI] [PubMed] [Google Scholar]
  68. Wall J. R., Triller H., Boucher A., Bernard N. F., Salvi M., Ludgate M. Antibodies reactive with an intracellular epitope of a recombinant 64 kDa thyroid and eye muscle protein in patients with thyroid autoimmunity and ophthalmopathy. J Endocrinol Invest. 1993 Dec;16(11):863–868. doi: 10.1007/BF03348946. [DOI] [PubMed] [Google Scholar]
  69. Wall J. R., Triller H., Chung F., Tsao M., Boucher A., Rodien P., Liberman A., Bernard N. Cross-reactive antibodies in the serum of balb/c mice immunized with thyroid or eye muscle membranes. J Endocrinol Invest. 1994 Feb;17(2):105–112. doi: 10.1007/BF03347694. [DOI] [PubMed] [Google Scholar]
  70. Wartofsky L. Has the use of antithyroid drugs for Graves' disease become obsolete? Thyroid. 1993 Winter;3(4):335–344. doi: 10.1089/thy.1993.3.335. [DOI] [PubMed] [Google Scholar]
  71. Weetman A. P., Yateman M. E., Ealey P. A., Black C. M., Reimer C. B., Williams R. C., Jr, Shine B., Marshall N. J. Thyroid-stimulating antibody activity between different immunoglobulin G subclasses. J Clin Invest. 1990 Sep;86(3):723–727. doi: 10.1172/JCI114768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Wiersinga W. M., Smit T., van der Gaag R., Mourits M., Koornneef L. Clinical presentation of Graves' ophthalmopathy. Ophthalmic Res. 1989;21(2):73–82. doi: 10.1159/000266782. [DOI] [PubMed] [Google Scholar]
  73. Winsa B., Mandahl A., Karlsson F. A. Graves' disease, endocrine ophthalmopathy and smoking. Acta Endocrinol (Copenh) 1993 Feb;128(2):156–160. doi: 10.1530/acta.0.1280156. [DOI] [PubMed] [Google Scholar]
  74. Young L. A. Dysthyroid ophthalmopathy in children. J Pediatr Ophthalmol Strabismus. 1979 Mar-Apr;16(2):105–107. doi: 10.3928/0191-3913-19790301-05. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES